Crescent Biopharma Q3: $289.4M Cash, $37.7M Quarterly Loss, CR-002 Trial Underway
CBIO sits 65% above its 52-week low of $8.72.
Summary
Crescent ended September with $289.4M in cash after raising $133.4M net in July, against a $37.7M quarterly loss and $71.6M of nine-month R&D spend. The CR-002 APOLLO trial started in Q4 2026, with first data expected in the second half of 2027.
Key Events · Earnings and Guidance · CBIO
-
Q3 Loss Widens on Clinical Spend
Net loss was $37.7M for Q3 and $85.8M for the nine months, with R&D up to $71.6M from $43.1M a year earlier on the ASCEND and APOLLO trial build-out.
-
Cash of $289.4M After July Raise
Cash and equivalents reached $289.4M at September 30, 2026, including $133.4M net from the July 2026 offering and $11.1M net from ATM sales; management says this funds operations for at least twelve months.
-
ATM Leaves $188.5M Overhang
545,524 shares were sold under the $200.0M ATM program for $11.1M net, leaving $188.5M available to sell into the market.
-
CR-002 Trial Started, Data 2H 2027
The FDA allowed the CR-002 IND in October 2026 and the global Phase 1/2 APOLLO trial began in Q4 2026, with initial data expected in the second half of 2027.
Analysis · CBIO · Life Sciences
Crescent burned $55.3M of operating cash in the first nine months while spending $71.6M on R&D. The $289.4M cash balance — boosted by $133.4M net from the July offering and $11.1M from the ATM — keeps the company funded for at least twelve months. That runway matters because the value hinges on clinical readouts: CR-001 ASCEND monotherapy data in Q1 2027, CR-003 proof-of-concept in Q1 2027, and CR-002 APOLLO initial data in the second half of 2027. The $188.5M still available under the ATM is a standing dilution overhang on top of the 38.2M shares already outstanding.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBIO was trading at $14.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $533.8M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.